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Editors’ Note 
Clinical Perspectives in Hepatology aims to engage two experts with opinions supporting 
differing perspectives on the management of a case. Typically, the case represents an area of 
debate or evolving practice in clinical hepatology. 
The patient presented below gives us the opportunity to discuss balloon-occluded retrograde 
transvenous obliteration (BRTO) for treatment of gastric varices. Although described since the 
mid-1990s and accepted as effective therapy, particularly in Japan, BRTO is used sporadically in 
the United States and Europe. In fact, it is not mentioned in the U.S. (AASLD) or European 
(EASL/Baveno V) guidelines. Hopefully, increased awareness of and expertise in this modality 
will generate the evidence-based data needed to establish the role and safety of BRTO in patients 
with gastric varices. 
Drs. Alia Dadabhai, Jonathan Fenkel, and Daniel Brown: Case Presentation 
A 50-year-old male with hepatitis C and alcohol related cirrhosis was hospitalized with his first 
upper gastrointestinal bleed secondary to isolated large gastric fundal varices, as confirmed by 
endoscopy. The patient was stabilized with conservative treatment. Magnetic resonance imaging 
(MRI) revealed thrombosis of the main, left, and right portal veins, with patency of the splenic 
vein and a spontaneous splenorenal shunt (Panels A and B). As endoscopic N-butyl-2-
cyanoacrylate injection was not available, and given the presence of portal vein thrombosis and a 
spontaneous splenorenal shunt, an elective balloon-occluded retrograde transvenous obliteration 
(BRTO) procedure was selected over a transjugular intrahepatic portosystemic shunt (TIPS).  
Using a right groin approach, the splenorenal shunt was catheterized and an 11-mm occlusion 
balloon (Python, Applied Medical, Rancho Santa Margarita, CA) inflated in the venous outflow. 
The varix was selectively catheterized back to the point of communication with the portal venous 
system. Foam sclerosant consisting of 3 parts air, 2 parts 3% Sotradecol (Angiodynamics, 
Queensbury, NY) and 1 part Ethiodol (Guerbet, Roissy, France) was mixed and approximately 
13 mL injected during catheter withdrawal, filling the varix and outflow vein back to the level of 
the balloon (panel C). Balloon inflation was maintained for 3 hours at which point the patient 
was restudied and satisfactory occlusion was confirmed. The patient was discharged without 
further bleeding and 3-month follow-up computed tomography (CT) confirmed collapse of the 
varices (panel D). 
Dr. Laine: The Endoscopist’s Perspective 
The Endoscopist’s Conventional Approach 
Endoscopic therapy with tissue adhesive (e.g., Nbutyl-cyanoacrylate [BCA]) is recommended for 
acute treatment of bleeding from isolated gastric varices in the fundus (IGV1), present in the 
patient described, and antrum (IGV2), and from type 2 gastroesophageal varices (GOV2), which 
extend from the esophagus into the fundus and tend to be long and tortuous.1,2 Following the 
acute episode, either BCA or TIPS is recommended for prevention of recurrent bleeding from 
IGV or GOV2. 
The Evidence to Support the Endoscopist’s Perspective 
Observational Studies of Endoscopic Therapy with BCA. Data assessing tissue adhesives come 
primarily from observational studies, with a limited number of randomized trials available. BCA 
is the most widely used tissue adhesive. In the U.S., BCA is approved for cerebral arteriovenous 
malformations but not for gastric varices. 2-Octyl-cyanoacrylate, approved for cutaneous wound 
closure in the U.S., has also been used. Case series indicate initial hemostasis of actively 
bleeding gastric varices with BCA from 82%- 100%, with rebleeding in large series 
generally_15%.3,4 Complications range from 0%-8% in most series and include bleeding due to 
early glue cast extrusion, distant embolism (e.g., brain, lung, spleen, heart), and sepsis.3,5 A 
majority of patients in most series have GOV rather than IGV but multivariate analysis in a 
recent large series found no significant association of gastric variceal type and rebleeding4 after 
BCA therapy. 
Clinical Trials of BCA Versus Other Therapies for Bleeding Gastric Varices 
Ligation. BCA had significantly better control of actively bleeding gastric varices in one 
randomized trial (87% versus 45%),6 but not another (93% versus 93%).7 Both studies showed 
significantly lower rates of long-term rebleeding with BCA (31% versus 54% and 22% versus 
44%).6,7 The greatest benefit of BCA appeared to be in patients with IGV1.7 Ligation had more 
complications (primarily treatment-induced ulcer bleeding) and a strong trend to decreased 
survival (29% versus 48%; P ¼ 0.05) in one study.6 A third randomized trial, restricted to 
GOV1, found significantly lower rates of persistent or recurrent bleeding (16% versus 35%) with 
BCA.8 
b-Blockers. BCA had significantly lower rates of gastric variceal rebleeding (15% versus 55%) 
and mortality (3% versus 25%) over a median of 26 months in a randomized trial.9 
TIPS. BCA had significantly more gastric variceal rebleeding (38% versus 11%) in a 
randomized trial.10 No significant difference was seen in survival or complications, although 
encephalopathy was more common with TIPS (26% versus 3%). Observational studies from the 
U.S. and U.K. raise the possibility that healthcare resource utilization may be higher with TIPS 
in the first 6-12 months, with more days in hospital due to TIPS complications.11,12 
Conclusions 
Endoscopic BCA is first-line therapy for acute treatment of bleeding gastric varices. If BCA is 
unsuccessful or unavailable, TIPS is recommended. TIPS is more effective than BCA in 
preventing recurrent bleeding, but has a higher rate of encephalopathy. In patients in whom TIPS 
is technically difficult or impossible, BRTO, as in the case presented, appears to be a very 
reasonable option. 
Dr. Brown: The Interventional Radiologist’s Perspective 
The Interventional Radiologist’s Conventional Approach 
TIPS is the standard approach for variceal bleeding that fails endoscopic management. BRTO 
can be performed when TIPS has a higher risk, such as portal vein thrombosis, high Model for 
Endstage Liver Disease (MELD) score, or encephalopathy. Our sclerosant preference is a 
mixture, as used in this case, which damages vascular endothelium within 2 minutes of contact 
and results in complete vascular thrombosis within 30 minutes. The minimum balloon inflation 
time is unknown—some authors use only 30 minutes,13 but we leave the balloon in place for 3 
hours, similar to others using Sotradecol.14 Patient selection is important to achieve procedural 
success, as BRTO is not feasible in all patients. A patent shunt connecting the varices/ portal 
system to the renal vein must be present. Once the varix is catheterized, outflow veins with 
systemic communication must be embolized to prevent unintentional infusion of the sclerosant 
into the systemic circulation. Embolization of these systemic communicators is necessary in 
approximately 50% of cases and is relatively straightforward.14 
The Evidence to Support the Interventional Radiologist’s Perspective 
Observational Studies of BRTO. When evaluating outcomes over multiple studies, Sabri et al.14 
described rebleeding rates following BRTO ranging from 0%- 9%. Varices were completely 
obliterated in 87%-100% of patients at follow-up endoscopy. Long term, freedom from recurrent 
gastric variceal hemorrhage of 90% at 8 years follow-up has been described.13 In this long-term 
follow-up study, the gastric varices were completely eradicated at endoscopy in 61 of 63 
patients. Technical failure due to anatomic unsuitability ranges from 7%-12%.13,15 Potential 
adverse effects of BRTO include development of esophageal varices and/or ascites resulting 
from elevation in portal pressure due to occlusion of a large gastrorenal shunt. In one series of 78 
patients,16 worsening of esophageal varices was observed in 29 patients, with incidences at 1, 3, 
and 5 years of 27%, 58%, and 66%, respectively. On the other hand, encephalopathy and 
synthetic function have been shown not to worsen following BRTO as portal perfusion 
increases.17,18 Surveillance endoscopy after BRTO and appropriate use of nonselective beta-
blockade and/or banding are required to prevent the possibility of esophageal variceal bleeding. 
Conclusions 
BRTO data, although largely uncontrolled, demonstrates excellent control of bleeding with 
durable obliteration of treated varices. The presence of a splenorenal shunt in the setting of 
factors increasing the risk for TIPS, such as portal vein thrombosis in the case presented, 
represents the ideal clinical application for BRTO. Expansion of use of this technique in the U.S. 
is likely over the next several years. 
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Figure 1: Baseline axial MRI demonstrates multiple prominent gastric fundal varices (White 
Arrows).  
 
 Figure 2: Coronal images from the same study demonstrate occlusive thrombus in the main 
(White Arrow), and left and right (Arrowheads) portal vein branches. 
 
 
 
Figure 3: With the balloon inflated (White Arrow), the sclerosing agent fills the gastrorenal shunt 
(White Arrowhead) and the gastric varices (Black Arrow). 
 
 Figure 4: CT scan obtained 3 months after the procedure demonstrates resolution of the varices 
with residual sclerosant in the veins (White Arrow). 
